Goldman Sachs Group Inc Neurocrine Biosciences Inc Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 685,865 shares of NBIX stock, worth $94.3 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
685,865
Previous 737,437
6.99%
Holding current value
$94.3 Million
Previous $81.6 Million
5.7%
% of portfolio
0.01%
Previous 0.01%
Shares
22 transactions
Others Institutions Holding NBIX
# of Institutions
660Shares Held
102MCall Options Held
290KPut Options Held
214K-
Black Rock Inc. New York, NY14.2MShares$1.95 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.81MShares$1.35 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.57MShares$766 Million0.42% of portfolio
-
State Street Corp Boston, MA4.47MShares$614 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.09MShares$424 Million0.04% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.2B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...